Dr. Lal Path Labs

Dr. Lal Path Labs

3,066.60
-41.40
(-1.33%)
ann
Company has added their latest Transcript18 hours ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
Market Cap
25,690.60 Cr
EPS
58.48
PE Ratio
48.35
Dividend Yield
0.77 %
52 Week High
3,540.00
52 Week Low
2,293.55
PB Ratio
12.01
Debt to Equity
0.10
Analyst Rating and Forecast
- By Refinitiv from23 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+69.57 %
+69.57 %
Hold
Hold+4.35 %
+4.35 %
Sell
Sell+26.09 %
+26.09 %
Forecast For
Actual

Company News

View All News
Caret
positive
Dr. Lal PathLabs has issued a postal ballot notice seeking shareholder approval for seven resolutions. The company proposes to introduce a new Employee Restricted Stock Unit Plan 2025 with up to 5,27,403 options, sourced from 3,19,023 fresh shares and 2,08,380 shares through secondary acquisition. The plan will be administered through the existing Dr. Lal PathLabs Employee Welfare Trust. Additionally, the company seeks approval to reduce the options reserve under its existing Employee Stock Option Plan 2022 from 12,50,278 to 7,22,875 options. The board has also recommended a 1:1 bonus share issue to celebrate ten years of listing, requiring an increase in authorized share capital from Rs 107.96 crore to Rs 200 crore. The bonus issue will be funded by capitalizing up to Rs 83.78 crore from the Securities Premium Account. The e-voting period runs from November 8, 2025, to December 7, 2025, with results to be announced by December 9, 2025.
positive
Dr. Lal PathLabs reported revenue of Rs. 731 crore for the quarter, marking 10.7% year-over-year growth, with half-year revenue reaching Rs. 1,400 crore (11% growth). The company recorded sample volume growth of 10.3% to 25.4 million and patient volume increase of 5% to 8.2 million. PAT grew 16.4% to Rs. 152 crore with a margin of 20.8%. EBITDA stood at Rs. 224 crore with a 30.7% margin. The Board approved an interim dividend of 70% (Rs. 7 per share) and a 1:1 bonus share issue. Revenue per patient increased 5.4% to Rs. 889. The company's Swasthfit program contributed 26% to quarterly revenues. Management guided for revenue growth of 11-12% for the financial year and EBITDA margins between 27-28%. The company is expanding its network with 15-20 new labs and 600-800 collection centers planned for the year. Net cash position stands at Rs. 1,367 crore.
positive
Dr Lal PathLabs announced expansion plans to open 15-20 new labs and 600-800 new collection centers by FY26. The company projects revenue growth of 11-12% for FY26 with EBITDA margin guidance of 27-28%. The expected margin reduction is now anticipated to be less severe than initially estimated. The company has become India's first lab to use AI for detecting cancer metastasis in lymph nodes and is developing its own AI algorithms for medical tests and operations.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
3,066.60
#1 25,690.60
#5 48.35
#1 2,554.80
#8 11.28
#1 492
#4 16.36
46.75
1,025.35
10,532.90
68.84
699.70
23.06
144
2.85
54.22
1,966.50
10,187.94
65.55
1,346.30
10.64
146
13.28
52.61
1,369.00
7,254.94
55.43
702.20
20.80
91
81.06
56.11
757.55
2,457.39
30.43
742.70
16.70
78
14.53
36.25
319.35
1,663.20
51.89
255.90
15.11
31
19.48
65.12
1,344.95
1,154.38
23.18
111.60
28.72
48
11.50
40.15
289.85
922.03
#1 -6.19
1,170.80
-18.47
-134
-35.12
38.22
409.05
799.38
28.63
147.80
#1 134.60
19
#1 444.44
72.61
142.70
99.44
66.59
41.80
13.28
2
0.00
33.13

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
11.28 %
Net Income Growth
35.88 %
Cash Flow Change
6.27 %
ROE
16.08 %
ROCE
4.10 %
EBITDA Margin (Avg.)
4.50 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
175
193
221
210
204
229
269
215
227
257
286
270
276
302
328
305
315
350
380
342
314
277
445
466
445
621
513
509
498
511
543
500
505
555
619
557
564
623
682
622
628
698
755
Expenses
128
140
196
119
144
162
182
160
170
184
200
206
203
217
231
227
235
240
257
246
244
218
305
314
309
418
357
388
364
385
390
376
375
395
424
398
401
432
458
443
434
478
507
EBITDA
47
53
25
91
60
67
87
55
57
73
86
64
73
84
98
78
80
110
124
96
69
60
140
152
136
203
156
121
133
126
153
124
130
161
196
159
163
191
224
179
195
220
249
Operating Profit %
25 %
26 %
9 %
37 %
27 %
27 %
31 %
23 %
23 %
26 %
28 %
22 %
24 %
26 %
27 %
22 %
22 %
28 %
30 %
25 %
19 %
18 %
29 %
31 %
28 %
31 %
28 %
22 %
25 %
23 %
27 %
23 %
24 %
27 %
30 %
26 %
27 %
28 %
31 %
26 %
28 %
29 %
31 %
Depreciation
8
7
7
7
7
6
7
7
8
7
8
8
11
9
9
10
10
16
18
19
20
18
20
20
20
19
21
31
38
36
39
38
38
35
36
36
37
35
35
36
36
35
41
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
4
4
4
4
4
4
5
5
9
12
9
11
9
9
8
8
7
7
6
6
5
5
5
5
Profit Before Tax
39
47
18
84
53
61
80
47
49
66
78
56
62
75
88
68
69
89
102
73
45
38
117
129
111
179
131
82
84
81
103
77
83
118
152
116
120
150
183
138
153
181
204
Tax
10
16
11
23
18
21
27
16
17
22
27
19
22
26
31
22
22
30
21
19
13
10
30
33
26
46
34
23
21
23
30
23
26
34
42
34
34
42
52
40
-2
47
51
Net Profit
29
31
7
61
35
40
53
31
32
44
51
36
40
50
57
46
47
59
81
55
33
28
87
96
85
134
96
58
62
58
72
54
57
84
111
82
86
108
131
98
156
134
152
EPS in ₹
5.28
5.61
0.99
7.37
4.17
4.88
6.47
3.78
3.80
5.40
6.19
4.39
4.88
6.00
6.92
5.56
5.72
7.14
9.77
6.56
3.94
3.45
10.34
11.44
10.10
15.87
11.49
6.93
7.41
6.97
8.64
6.37
6.84
9.95
13.16
9.77
10.13
12.79
15.52
11.60
18.57
15.88
18.05

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
475
625
764
916
1,091
1,374
1,661
2,353
2,386
2,456
2,717
Fixed Assets
150
166
190
208
209
413
447
1,375
1,305
1,228
1,168
Current Assets
282
424
511
623
814
893
1,145
875
973
1,127
1,364
Capital Work in Progress
1
4
18
10
3
11
10
15
5
6
4
Investments
38
64
105
145
185
164
59
66
150
114
327
Other Assets
286
391
452
554
694
786
1,145
898
926
1,109
1,218
Total Liabilities
475
625
764
916
1,091
1,374
1,661
2,353
2,386
2,456
2,717
Current Liabilities
112
91
74
116
138
227
274
500
470
465
402
Non Current Liabilities
20
24
28
8
1
93
111
310
216
105
108
Total Equity
343
510
662
792
951
1,054
1,276
1,544
1,700
1,885
2,207
Reserve & Surplus
260
424
577
734
890
974
1,162
1,425
1,583
1,766
2,089
Share Capital
81
83
83
83
83
83
83
83
83
84
84

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
8
-5
2
37
64
67
48
134
-115
97
-68
Investing Activities
-114
-164
-137
-172
-100
-26
-212
-449
-287
-24
-303
Operating Activities
122
159
171
197
219
284
398
447
456
535
569
Financing Activities
-1
0
-32
13
-55
-190
-139
136
-283
-414
-334

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
55.23 %
55.23 %
55.23 %
55.23 %
55.23 %
55.05 %
55.05 %
55.05 %
55.03 %
55.01 %
54.61 %
54.60 %
54.60 %
54.60 %
53.92 %
53.91 %
53.91 %
53.79 %
53.21 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.00 %
1.83 %
0.00 %
0.00 %
0.00 %
26.15 %
25.42 %
26.82 %
26.82 %
23.91 %
21.68 %
21.86 %
DIIs
6.47 %
5.61 %
4.84 %
5.58 %
5.69 %
5.30 %
5.09 %
6.19 %
6.55 %
7.33 %
7.97 %
8.61 %
9.69 %
12.71 %
12.89 %
13.17 %
16.08 %
17.91 %
18.49 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
5.70 %
6.24 %
6.93 %
7.45 %
9.03 %
10.44 %
8.24 %
9.03 %
9.50 %
9.31 %
8.37 %
7.26 %
6.47 %
4.91 %
4.10 %
4.01 %
4.11 %
5.23 %
5.19 %
Others
32.60 %
32.92 %
32.99 %
31.74 %
30.05 %
29.22 %
31.63 %
27.73 %
27.09 %
28.35 %
29.05 %
29.53 %
3.09 %
2.35 %
2.27 %
2.10 %
2.00 %
1.38 %
1.25 %
No of Share Holders
68,845
94,123
1,25,953
1,35,068
1,71,846
1,84,508
1,71,602
1,79,636
1,80,163
1,74,444
1,60,679
1,49,901
1,46,741
1,31,189
1,16,606
1,16,236
1,15,699
1,18,656
1,12,703

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 4.5 6 12 20 12 12 24 24
Dividend Yield (%) 0.00 0.34 0.43 0.43 0.44 0.77 0.67 0.53 0.97 0.77

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
07 Nov 2025 DIVIDEND Dividend
₹ 7.00 /share
07 Nov 2025 3,089.40 3,108.00
10 Feb 2021 DIVIDEND Dividend
₹ 6.00 /share
09 Feb 2021 2,245.95 2,408.65
22 Jul 2021 DIVIDEND Dividend
₹ 8.00 /share
20 Jul 2021 2,854.95 3,372.15
22 Aug 2021 DIVIDEND Dividend
₹ 6.00 /share
18 Aug 2021 3,732.50 3,852.65
23 Jun 2022 DIVIDEND Dividend
₹ 6.00 /share
22 Jun 2022 2,206.55 1,972.85
09 Aug 2022 DIVIDEND Dividend
₹ 6.00 /share
05 Aug 2022 2,170.30 2,415.45
11 Aug 2023 DIVIDEND Dividend
₹ 6.00 /share
11 Aug 2023 1,949.85 2,364.35
11 Aug 2023 DIVIDEND Dividend
₹ 6.00 /share
11 Aug 2023 2,483.50 2,364.35
13 Feb 2024 DIVIDEND Dividend
₹ 12.00 /share
13 Feb 2024 2,517.40 2,458.75
10 Jun 2024 DIVIDEND Dividend
₹ 6.00 /share
10 Jun 2024 2,231.55 2,797.75
29 Jun 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Jun 2024 2,231.55 2,779.70
20 Aug 2024 DIVIDEND Dividend
₹ 6.00 /share
20 Aug 2024 3,168.45 3,310.20
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 3,392.30 3,309.90
05 Nov 2024 DIVIDEND Dividend
₹ 6.00 /share
05 Nov 2024 3,309.90 3,068.10
30 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Jan 2025 2,842.75 2,759.00
05 Feb 2025 DIVIDEND Dividend
₹ 6.00 /share
05 Feb 2025 2,759.00 2,829.70
06 Feb 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
06 Feb 2025 2,792.50 2,792.50
25 Apr 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
25 Apr 2025 2,714.10 2,788.20
06 Jun 2025 DIVIDEND Dividend
₹ 6.00 /share
06 Jun 2025 2,788.20 2,856.80
28 Jun 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Jun 2025 2,788.20 2,771.25
31 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jul 2025 3,017.00 3,099.10
06 Aug 2025 DIVIDEND Dividend
₹ 6.00 /share
06 Aug 2025 3,099.10 3,194.40
31 Oct 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Oct 2025 3,071.20 3,089.40

Announcements

Shareholder Meeting / Postal Ballot-Notice of Postal Ballot31 minutes ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript18 hours ago
Announcement under Regulation 30 (LODR)-Newspaper Publication5 days ago
Receipt Of An Assessment Order And Demand Notice Issued By Income Tax Department6 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome6 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation6 days ago
Record Date For 2Nd Interim Dividend FY 2025-266 days ago
Introduction Of Dr. Lal Pathlabs Employee RSU 2025 (ESOP Scheme)6 days ago
Announcement under Regulation 30 (LODR)-Dividend Updates6 days ago
Corporate Action-Board recommends Bonus Issue6 days ago
Financial Results For The Quarter And Half Year Ended September 30 20256 days ago
Board Meeting Outcome for Outcome Of The Board Meeting Held On October 31 20256 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
Board Meeting Intimation for Notice Of Board MeetingOct 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsSep 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 31, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Amendment In Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive InformationJul 31, 2025
Record Date For Interim Dividend FY 2025-26Jul 31, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesJul 31, 2025
Board Meeting Outcome for Outcome Of Board Meeting - July 31 2025Jul 31, 2025
Results- Financial Results For The Quarter Ended June 30 2025Jul 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 24, 2025
Board Meeting Intimation for Declaration Of Financial Results For The Quarter Ended June 30 2025 And Interim Dividend If AnyJul 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 28, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMJun 28, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Letter Dispatched To The Members Of The Company- Weblink Of The Annual Report FY 2024-25Jun 04, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jun 04, 2025
31St Annual General Meeting To Be Held On June 28 2025Jun 04, 2025
Reg. 34 (1) Annual Report.Jun 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 02, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 30, 2025
Amended Trust DeedMay 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Flexi Cap Direct Plan-Growth
0.00%
-2000000
-0.73%
-0.85%
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth
0.00%
-823007
-1.10%
-1.10%
SBI Large & Midcap Fund Direct Plan-Growth
0.00%
-650000
-0.60%
-0.65%
Nippon India Small Cap Fund Direct- Growth
0.00%
-645485
-0.30%
-0.33%
Nippon India Pharma Fund Direct-Growth
0.00%
-609112
-2.34%
-2.41%
HDFC ELSS Tax Saver Fund Direct Plan-Growth
0.00%
-570000
-1.07%
-1.14%
Sundaram Mid Cap Fund Direct-Growth
0.00%
-512777
-1.27%
-1.37%
PGIM India Midcap Fund Direct-Growth
0.00%
-388808
-1.07%
-1.13%
SBI Dividend Yield Fund Direct - Growth
0.00%
-330000
-1.13%
-1.22%
HDFC Retirement Savings Fund Equity Plan Direct-Growth
0.00%
-315000
-1.47%
-1.50%
Tata Balanced Advantage Fund Direct - Growth
0.00%
-301566
-0.96%
-0.98%
Sundaram Large and Mid Cap Fund Direct-Growth
0.00%
-285000
-1.32%
-1.59%
Nippon India Multi Cap Fund Direct-Growth
0.00%
-266409
-0.18%
-0.27%
SBI ESG Exclusionary Strategy Fund Direct Plan-Growth
0.00%
-250000
-1.39%
-1.48%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.00%
-228237
-1.46%
-0.69%
Tata Multicap Fund Direct - Growth
0.00%
-216169
-2.17%
-2.34%
NJ Balanced Advantage Fund Direct - Growth
0.00%
-187978
-1.54%
-1.62%
NJ Flexi Cap Fund Direct - Growth
0.00%
-178990
-2.31%
-2.45%
Edelweiss Small Cap Fund Direct - Growth
0.00%
-173698
-1.07%
-0.27%
Mirae Asset Small Cap Fund Direct-Growth
0.00%
-154919
-2.00%
-2.37%
HDFC Multi Asset Fund Direct-Growth
0.00%
-130000
-0.82%
-0.88%
Baroda BNP Paribas Multi Cap Fund Direct-Growth
0.00%
-125800
-1.33%
-1.14%
Tata India Pharma & Healthcare Fund Direct-Growth
0.00%
-122120
-2.94%
-3.09%
Tata India Innovation Fund Direct-Growth
0.00%
-120270
-2.21%
-2.31%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-117984
-1.94%
-2.04%

Technical Indicators

RSI(14)
Neutral
46.75
ATR(14)
Less Volatile
96.87
STOCH(9,6)
Neutral
54.68
STOCH RSI(14)
Neutral
63.95
MACD(12,26)
Bullish
8.79
ADX(14)
Weak Trend
12.51
UO(9)
Bearish
43.52
ROC(12)
Downtrend And Accelerating
0.00
WillR(14)
Neutral
-63.38

About Dr. Lal Path Labs

Dr Lal PathLabs is a leading diagnostic healthcare service provider in India. The company operates a nationwide network of medical laboratory centers, offering over 5000 diagnostic tests and related healthcare services. Its infrastructure includes a National Reference Laboratory in New Delhi, Regional Reference Labs in Kolkata, Bangalore, and Mumbai, 371 clinical laboratories, 5,102 patient service centers, and 10,938 pickup points as of March 31, 2023. The company provides services to individual patients, hospitals, healthcare providers, and corporate customers. Its test catalog includes 481 test panels, 2763 pathology tests, and 1947 radiology and cardiology tests. Dr Lal PathLabs has expanded through acquisitions and has several domestic and international subsidiaries. The company continues to grow its network and enhance its technological capabilities to improve its diagnostic services.
Listing Date
23 Dec, 2015(9 Years, 15 days)
Chairperson NameArvind Lal